Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques

Vierboom, Michel; Chenine, Agnès Laurence; Darrah, Patricia A.; Vervenne, Richard A. W.; Boot, Charelle; Hofman, Sam; Sombroek, Claudia C.; Dijkman, Karin; Khayum, Mohamed A; Stammes, Marieke A.; Haanstra, Krista G.; Hoffmann, Chantal; Schmitt, D; Silvestre, Nathalie; White, Alexander G.; Borish, H. Jacob; Seder, Robert A.; Ouaked, Nadia; Leung–Theung–Long, Stéphane; Inchauspé, Geneviève; Anantha, Ravi; Limbach, M. Paullin; Evans, Thomas G.; Casimiro, Danilo R.; Lempicki, Maria; Laddy, Dominick J.; Bonavia, Aurelio; Verreck, Frank A. W.

doi:10.1038/s41541-020-0189-2

Cited by 16 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional work is needed to explore whether Ad vector-based influenza vaccines could be used in all segments of the population. The use of the prime-boost approach with two different Ad vectors [54,141], Ad and another viral vector [142][143][144][145][146][147], or Ad vector and DNA immunization [148][149][150][151] will confer a considerably higher level of immune responses, especially in the elderly. Author Contributions: All authors have read and agreed to the published version of the manuscript.…”

Section: Discussionmentioning

confidence: 99%

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

et al. 2020

View full text Add to dashboard Cite

Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe. In this review, we discuss the progress in the development of Ad vector-based influenza vaccines and their potential in designing a universal influenza vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A similar result was observed in cattle using BCG as prime, AdAg85A as a booster and tested against M. bovis challenge ( Dean et al, 2014 ). Interestingly, in rhesus macaques using BCG as prime and a boost of Ad5 vector caring TB antigens (M72, ESAT-6/Ag85b, or ESAT-6/Rv1733/Rv2626/RpfD) showed no enhanced protection against infection compared to BCG used alone ( Darrah et al, 2019 ), and the same result was observed using a regimen of prime-boost strategy with ChAd3 and MVA ( Vierboom et al, 2020 ).…”

Section: Use Of Adenoviral Vectors As Vaccinesmentioning

confidence: 91%

The use of adenoviral vectors in gene therapy and vaccine approaches

et al. 2022

View full text Add to dashboard Cite

Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.

show abstract

“…In 2020, different prime-boost strategies using the chimpanzee Ad3 (ChAd3) and MVA vectors expressing Ag85B, ESAT-6, Rv1733, Rv2626, and RpfD, were evaluated for immunogenicity and protective efficacy in highly susceptible rhesus macaques through different inoculation routes such as i.m., i.d., and aerosol. However, although specific immune responses were induced, none of these vaccine strategies conferred a protective effect compared to non-vaccinated controls ( 120 ).…”

Section: Recombinant Virus-vectored Tb Vaccinesmentioning

confidence: 99%

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Lowrie

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis, remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissible form of the disease. Thus, the lack of an optimal TB vaccine is one of the key barriers to TB control. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the controlled human challenge model. In the TB vaccine field, recent progress also facilitated the deployment of an effective TB vaccine. In this review, we provide an update on the current virus-vectored TB vaccine pipeline and summarize the latest findings that might facilitate TB vaccine development. In detail, on the one hand, we provide a systematic literature review of the virus-vectored TB vaccines are in clinical trials, and other promising candidate vaccines at an earlier stage of development are being evaluated in preclinical animal models. These research sharply increase the likelihood of finding a more effective TB vaccine in the near future. On the other hand, we provide an update on the latest tools and concept that facilitating TB vaccine research development. We propose that a pre-requisite for successful development may be a better understanding of both the lung-resident memory T cell-mediated mucosal immunity and the trained immunity of phagocytic cells. Such knowledge could reveal novel targets and result in the innovative vaccine designs that may be needed for a quantum leap forward in vaccine efficacy. We also summarized the research on controlled human infection and ultra-low-dose aerosol infection murine models, which may provide more realistic assessments of vaccine utility at earlier stages. In addition, we believe that the success in the ongoing efforts to identify correlates of protection would be a game-changer for streamlining the triage of multiple next-generation TB vaccine candidates. Thus, with more advanced knowledge of TB vaccine research, we remain hopeful that a more effective TB vaccine will eventually be developed in the near future.

show abstract

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques

Cited by 16 publications

References 45 publications

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

The use of adenoviral vectors in gene therapy and vaccine approaches

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Contact Info

Product

Resources

About